Navigation Links
Pharmion and MethylGene Report Preliminary MGCD0103 Clinical Data at the 2007 AACR-NCI-EORTC International Conference
Date:10/24/2007

ecutive Officer of MethylGene.

"There is tremendous unmet need in pancreatic cancer, and the pre-clinical and clinical data are encouraging," said Dr. Andrew Allen, executive vice president and chief medical officer of Pharmion. "If the signals are sustained, we will move forward with a registrational study in this context, where inhibition of histone deacetylation may enhance the efficacy of gemcitabine. It is possible that the HDAC class-selectivity of MGCD0103, theoretically driving a narrower toxicity profile than pan-HDAC inhibitors, is particularly advantageous in combination with cytotoxic agents."

The combination of MGCD0103 and Gemzar appeared to be well-tolerated in patients with solid tumors which suggest compatibility between the two agents. The 90mg dose is consistent with the single-agent dose for MGCD0103 that is under investigation in Phase II trials for hematologic malignancies. The most common toxicities observed were fatigue, vomiting, anorexia, diarrhea, nausea, headaches and decreased hemoglobin (anemia), all of which were less than or equal to grade 3. In addition, grade 4 hyperkalemia and thrombocytopenia were reported in one patient. Based on determination of the recommended Phase II dose of 90mg and clinical activity, the Phase II portion of the trial has been initiated in gemcitabine-naive patients with metastatic or non-resectable locally-advanced pancreatic cancer. This portion of the study will enroll up to 40 patients.

About Pharmion

Pharmion is a leading global oncology company focused on acquiring, developing and commercializing innovative products for the treatment of hematology and oncology patients in the U.S., Europe and additional international markets. Pharmion has a number of products on the market including the world's first approved epigenetic drug, Vidaza(R), a DNA demethylating agent. For additional information about Pharmion, please visit the company's website at '/>"/>

SOURCE Pharmion Corporation
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
2. Pharmion to Present Clinical Data on Commercial and Pipeline Products at 2007 American Society of Clinical Oncology (ASCO) Meeting
3. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
4. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
5. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
6. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
7. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
8. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
9. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
10. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
11. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2008)..., , CHICAGO, Dec. 1 /PRNewswire-USNewswire/...ased cerebral blood flow and a greater number of s...ings presented today at the annual meeting of the ... , The study, conducted at the University of...st to compare brain scans of older adults who exer...
(Date:11/26/2008)...OCHESTER, Minn., Nov. 26 /PRNewswire-USNewswire/ -...ward are at significantly increased risk of develo...to findings of a Mayo Clinic study published this... American Academy of Pediatrics. , , The re...407 patients with strabismus (misaligned eyes) and...
(Date:11/25/2008)...esults reveal most respondents against expanding s..., , LITTLE FALLS, N.J., Nov. 25 /PRNewswire/...tin may lower the cardiovascular risk of healthy p...rsal statin use in older adults, according to a na... 1,212 participants took part in the online poll c...
(Date:11/25/2008)...AS VEGAS, Nov. 25 Cardio...d: CVBT), announced today that it has,dosed the f...ACORD Phase II,clinical trial to treat patients w...iogenesis for the treatment of CORonary heart Dise...lind, placebo-controlled doses in approximately 12...
Breaking Medicine Technology:Exercise Helps Prevent Age-Related Brain Changes in Older Adults 2Exercise Helps Prevent Age-Related Brain Changes in Older Adults 3Eye Divergence in Children Triples Risk of Mental Illness 2Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows 2Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows 3CVBT Doses First Patient in its Phase II Clinical Trial for Severe Coronary Heart Disease 2CVBT Doses First Patient in its Phase II Clinical Trial for Severe Coronary Heart Disease 3Single Mutation in Mitochondrial DNA Weakens Heart Muscles 11983 1Single Mutation in Mitochondrial DNA Weakens Heart Muscles 11983 2 244 million award to improve detection of acute kidney injury after cardiac surgery 11979 1 244 million award to improve detection of acute kidney injury after cardiac surgery 11979 2Coalition for a Competitive Pharmaceutical Market Launches New Print Ad Campaign Highlighting Need for Meaningful Biogenerics Legislation 3319 1Thompson Demands Solution to Formaldehyde Trailer Crisis 11972 1Thompson Demands Solution to Formaldehyde Trailer Crisis 11972 2
...ON, January 29, 2007 /PRNewswire-USNewswire/ -- Re...e President,s,Malaria Coordinator, announced his i...y Coordinator of the President,s Malaria,Initiativ...he U.S.,Public Heath Service and has most recently...on, at the Global Fund to Fight,AIDS, Tuberculosis...
...PHIA, July 3, 2007 ? Researchers in Slovakia have,...man adipose, or,fat, tissue and engineer them into...stroy tumors like tiny homing missiles., This gene...umor metastases that evade current detection techn...the July 1 issue of Cancer,Research, a journal of ...
Other Medicine Technology:Studies of Drug Resistance May Lead to Individual Therapy for Rare,Cancers 2Fat Kills Cancer: Turning Stem Cells from Fat Tissue into,Personalized, Cancer-Targeted Therapeutics 2Fat Kills Cancer: Turning Stem Cells from Fat Tissue into,Personalized, Cancer-Targeted Therapeutics 3
(Date:12/1/2008)...heir DNA is damaged, in a process known as cellula...ading to unregulated cell division and therefore c...k,s issue of PLoS Biology , has found that when t...their surrounding environment. This causes inflamm...lopment of age-related diseases including, ironica...
(Date:12/1/2008)... Sloan-Kettering Cancer Center, New York, have dev...f genes for therapeutic purposes, and used this to... Small, noncoding RNA molecules known as miRNAs ar...In the study, the miRNA miR-181a was harnessed to ...n as T cells at different stages of their developm...
(Date:12/1/2008)...Westaim Corporation today announced it has requisi...T Pharmaceuticals Corp. to consider a return of ca...15 million or US$0.80 per share. Westaim will cont...of its 74.5 per cent stake in NUCRYST. Under the A...of Directors has 20 days to call a meeting of shar...
(Date:12/1/2008)...repreneur, television and,radio host Ryan Seacres...,Bendheim will be honored by the Cedars-Sinai Boa...Gala, December 2, 2008, at the Hyatt Regency Centu...rd of Governors, co-chairs the,event with Debbee ...e "Road To,A Cure" Gala is sponsored by Lexus, wh...
Breaking Medicine News(10 mins):Health News:Escape cancer, but age sooner? The dark side of the tumor suppressing process 2Health News:The Westaim Corporation requisitions meeting of shareholders of NUCRYST Pharmaceuticals to return capital to NUCRYST shareholders 2Health News:Cedars-Sinai Board of Governors to Honor Ryan Seacrest & John Bendheim at Annual 'Road To A Cure' Gala 2
...a, which is a common problem for breast cancer pat... swelling, most often in the arms or legs, and dev...g, impaired, damaged, or removed. Secondary lymphe...ery, scar tissue formation, trauma,// deep vein th...
...rch has shown that those who smoke face the highes...non-smokers respectively. However, researchers add...causal path can be established. A study of cross-s...hold Survey on Drug Abuse(collected from different...
...rs have found that children who complain that they... a diagnosis that can be easily missed. They said ...ight time behaviours and who do not have a family ... of the disease called stationary night// blindnes...
...for potential medical problems, according to earli...n for adults. The rates for babies in hospitals ar...an Academy of Pediatrics (AAP) and the Agency for ... may help prevent medical errors in children.// Th...
Other Medicine News:
Our electronic charts include a Patient Face Sheet, summarizing patient information and as many as six custom tabs, so you can customize which information is important for you to document. In additio
...mprises the core applications for health informati...onic medical record. The suite includes applicatio...ncy completion & release of information., Imp...nment, CHARMS 2000 modules leverage the most sophi...
Clinician's Desktop provides users the tools needed to coordinate information. Utilizing client/server technology Clinicians Desktop provides users with electronic medical records.
...le is a PDA medical software for patient tracking,...r Pocket PC PDA. With CPT codes and cross-linked I...ing, it will make your patient tracking, charge ca...ut-patient or in-patient environment. This PDA med...
Medicine Products: